Key Highlights

  • Revenue was USD 21.72 million against an estimate of USD 18.70 million.
  • Loss per share was USD 0.16 against an estimate of a USD 0.21 loss.
  • Net loss was USD 25.30 million, against USD 40.97 million a year earlier.
  • Cash and cash equivalents were USD 189.2 million at September 30.

ADC Therapeutics (NYSE:ADCT) reported third quarter 2026 total Revenue of USD 21.72 million, against an estimate of USD 18.70 million and USD 16.43 million in the third quarter of 2025. The loss per share was USD 0.16, compared with an estimate of a USD 0.21 loss and a USD 0.30 loss a year earlier.

Net loss was USD 25.30 million, against USD 40.97 million in the prior-year quarter. The loss from operations was USD 14.35 million, compared with USD 30.97 million.

Product Revenue and Costs

Product revenues, net, were USD 21.0 million, compared with USD 15.8 million, an increase of USD 5.3 million, or 33.4%. Cost of product sales was USD 2.0 million, against USD 1.2 million, an increase of USD 0.8 million, or 64.7%.

Total operating expenses were USD 36.07 million, compared with USD 47.40 million a year earlier. The filing's income statement shows total revenue, net, of USD 61.82 million for the nine months, against USD 58.30 million.

Operating Expenses

Research and development expenses were USD 14.7 million, compared with USD 26.8 million, a decrease of USD 12.1 million, or 45.0%. Selling and Marketing expenses were USD 8.7 million, against USD 10.7 million, a decrease of USD 2.0 million, or 18.8%.

General and administrative expenses were USD 10.7 million, against USD 8.3 million, an increase of USD 2.4 million, or 28.9%. For the nine months, net loss was USD 74.84 million, compared with USD 136.21 million, and the loss from operations was USD 65.01 million, against USD 103.58 million.

Liquidity and Agreements

As of September 30, 2026, the company had cash and cash equivalents of USD 189.2 million and believes its current cash position and Capital resources are sufficient to fund operations and meet capital requirements for at least the next twelve months from the date of the report.

The filing notes that on February 18, 2026, the company entered into an amendment to its Royalty purchase agreement with entities managed by HealthCare Royalty Management. Under the royalty purchase agreement, the company received gross proceeds of USD 225.0 million upon closing and an additional USD 75.0 million during 2023 upon the first commercial sale of ZYNLONTA in the United Kingdom or any European Union country. On August 15, 2022, it also entered into a Share Purchase Agreement with the lenders under its Loan agreement to purchase 733,568 common shares.

The filing also states that the company is pursuing expansion into earlier lines of therapy and indolent lymphomas through company-sponsored trials and investigator-initiated studies.

ADC Therapeutics Q3 2026 Earnings: Key Takeaways

ADC Therapeutics reported third quarter 2026 total revenue of USD 21.72 million and a loss per share of USD 0.16. Product revenues were USD 21.0 million, net loss was USD 25.30 million, and cash and cash equivalents were USD 189.2 million.